Brentuximab Vedotin (BV) is a chimeric anti-CD30 antibody, conjugated to anti-tubulin mono-methyl-auristatin. The AETHERA trial revealed increased PFS when BV is used as maintenance therapy for 16 cycles in high risk Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT). However, this schedule is associated with high cost and significant toxicity. Our objective is to assess the safety and efficacy of four cycles Brentuximab Vedotin as consolidation after ASCT for relapsed/refractory (R/R) HL. We identified 20 consecutive adult patients with R/R HL treated with BV for four cycles as consolidation after ASCT. The indications for BV consolidation included primary refractory disease in 12 patients (60%), early relapse in 6 patients (30%) and extra-nodal involvement in two patients (10%). After a median follow up of 27 months, five (25%) patients relapsed. The median time to relapse was 6 months. Median PFS and OS were not reached. No significant toxicities were reported.
April 29, 2020
- ASCO – Lung CancerASCO.20 Virtual Scientific Program, held May 29 - 31, brought professionals from all over the world together to hear the brightest minds in oncology present state-of-the-art treatment modalities and new therapies.
- AACR-2020The American Association for Cancer Research is the world's oldest and largest professional association related to cancer research.
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
ASCO 2019The 2019 ASCO Annual Meeting, taking place May 31-June 4 in Chicago, will bring together more than 32,000 oncology professionals from across the globe. The theme of this year’s conference is Caring for Every Patient, Learning From Every Patient.